- Sareum Holdings said a trial of a cancer treatment by licencing partner Sierra Oncology was expected to be completed in April 2020.

Patients in the SRA737 treatment monotherapy trial were currently being dosed in 15 cancer centres in the UK.

A combination trial with SRA737 and low-dose gemcitabine was active in six centres in Spain and a further 14 in the UK, and was currently estimated to complete in June 2020.

Chairman Stephen Parker gave the update in speech notes for the company's annual general meeting.

He also said the company continued to engage with potential partners, with a view to securing commercial licences for its products and programmes.

It was seeing early interest in its Aurora/FLT3 programme, into which it had discontinued further investment while it found a licence partner, Parker said.

At 8:25am: [LON:SAR] Sareum Holdings PLC share price was -0.03p at 0.58p

Story provided by